Boxer Capital 13F annual report
Boxer Capital is an investment fund managing more than $1.9 trillion ran by Aaron Davis. There are currently 57 companies in Mr. Davis’s portfolio. The largest investments include SpringWorks Therapeutics and Cytokinetics Inc, together worth $316 billion.
$1.9 trillion Assets Under Management (AUM)
As of 8th May 2024, Boxer Capital’s top holding is 3,421,541 shares of SpringWorks Therapeutics currently worth over $168 billion and making up 8.3% of the portfolio value.
Relative to the number of outstanding shares of SpringWorks Therapeutics, Boxer Capital owns less than approximately 0.1% of the company.
In addition, the fund holds 2,100,000 shares of Cytokinetics Inc worth $147 billion, whose value grew 80.8% in the past six months.
The third-largest holding is Revolution Medicines Inc worth $138 billion and the next is Tyra Biosciences Inc worth $106 billion, with 6,448,359 shares owned.
Currently, Boxer Capital's portfolio is worth at least $1.9 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Boxer Capital
The Boxer Capital office and employees reside in San Diego, California. According to the last 13-F report filed with the SEC, Aaron Davis serves as the Chief Executive Officer at Boxer Capital.
Recent trades
In the most recent 13F filing, Boxer Capital revealed that it had opened a new position in
Sarepta Therapeutics Inc and bought 650,000 shares worth $84.1 billion.
This means they effectively own approximately 0.1% of the company.
Sarepta Therapeutics Inc makes up
5.4%
of the fund's Health Care sector allocation and has decreased its share price by 15.6% in the past year.
The investment fund also strengthened its position in Revolution Medicines Inc by buying
295,200 additional shares.
This makes their stake in Revolution Medicines Inc total 4,279,464 shares worth $138 billion.
Revolution Medicines Inc soared 40.8% in the past year.
On the other hand, there are companies that Boxer Capital is getting rid of from its portfolio.
Boxer Capital closed its position in Prometheus Biosciences Inc on 15th May 2024.
It sold the previously owned 1,897,500 shares for $209 billion.
Aaron Davis also disclosed a decreased stake in Nuvalent Inc by approximately 0.1%.
This leaves the value of the investment at $84.1 billion and 1,120,192 shares.
One of the largest hedge funds
The two most similar investment funds to Boxer Capital are Swan Global Investments and Fullerton Fund Management Co. They manage $2.03 trillion and $2.03 trillion respectively.
Aaron Davis investment strategy
Boxer Capital’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 77.3% of
the total portfolio value.
The fund focuses on investments in the United States as
59.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
4% of the total holdings value.
On the other hand, small-cap stocks make up only 3.5% of the portfolio.
The average market cap of the portfolio companies is close to $2.28 billion.
The complete list of Boxer Capital trades based on 13F SEC filings
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Prometheus Biosciences Inc |
Closed
1,897,500
|
$208,725,000,000 | |
| SpringWorks Therapeutics, Inc. |
No change
3,421,541
|
$168,408,248,000 | 8.32% |
| Cytokinetics Inc |
No change
2,100,000
|
$147,231,000,000 | 7.27% |
| Revolution Medicines Inc |
7.41%
4,279,464
|
$137,927,125,000 | 6.81% |
| Tyra Biosciences Inc |
No change
6,448,359
|
$105,753,088,000 | 5.22% |
| Apellis Pharmaceuticals Inc |
9.52%
1,726,000
|
$101,454,280,000 | 5.01% |
| IDEAYA Biosciences, Inc. |
No change
2,202,812
|
$96,659,391,000 | 4.77% |
| Mirati Therapeutics Inc |
Closed
2,000,000
|
$90,620,000,000 | |
| Merus N.V |
No change
1,900,000
|
$85,557,000,000 | 4.23% |
| Sarepta Therapeutics Inc |
Opened
650,000
|
$84,149,000,000 | 4.16% |
| Nuvalent Inc |
7.44%
1,120,192
|
$84,115,217,000 | 4.15% |
| BeiGene Ltd |
No change
500,000
|
$78,195,000,000 | 3.86% |
| Tango Therapeutics Inc |
15.09%
8,198,642
|
$65,097,217,000 | 3.22% |
| Nkarta, Inc. |
Opened
5,607,350
|
$60,615,454,000 | 2.99% |
| Fate Therapeutics Inc |
557.27%
8,215,910
|
$60,304,779,000 | 2.98% |
| Reata Pharmaceuticals Inc |
Closed
1,230,004
|
$46,727,852,000 | |
| Avidity Biosciences, Inc. |
54.05%
1,727,388
|
$44,082,942,000 | 2.18% |
| Akero Therapeutics Inc |
101.65%
1,676,733
|
$42,354,276,000 | 2.09% |
| Sage Therapeutics Inc |
Closed
1,094,000
|
$41,725,160,000 | |
| Rocket Pharmaceuticals Inc |
No change
1,466,051
|
$39,495,414,000 | 1.95% |
| Argenx Se |
Opened
100,000
|
$39,372,000,000 | 1.94% |
| Centessa Pharmaceuticals Plc |
Closed
1,251,137
|
$38,785,245,000 | |
| Legend Biotech Corp |
Opened
600,000
|
$33,654,000,000 | 1.66% |
| Axsome Therapeutics Inc |
No change
400,000
|
$31,920,000,000 | 1.58% |
| Arcus Biosciences Inc |
11.87%
1,602,200
|
$30,249,536,000 | 1.49% |
| AnaptysBio Inc |
No change
1,300,000
|
$29,276,000,000 | 1.45% |
| Amicus Therapeutics Inc |
Closed
2,325,000
|
$28,388,250,000 | |
| Ventyx Biosciences Inc |
Closed
850,000
|
$27,871,500,000 | |
| Pmv Pharmaceuticals Inc |
Closed
3,163,795
|
$27,525,016,000 | |
| Immunovant Inc |
Opened
825,000
|
$26,655,750,000 | 1.32% |
| Bellus Health Inc |
Closed
3,200,000
|
$26,304,000,000 | |
| Xenon Pharmaceuticals Inc |
No change
600,000
|
$25,830,000,000 | 1.28% |
| Arvinas Inc |
305.74%
608,614
|
$25,123,586,000 | 1.24% |
| iTeos Therapeutics, Inc. |
16.25%
1,804,058
|
$24,607,351,000 | 1.22% |
| Viking Therapeutics Inc |
80.00%
300,000
|
$24,600,000,000 | 1.22% |
| Oric Pharmaceuticals, Inc. |
64.38%
1,732,571
|
$23,822,851,000 | 1.18% |
| Kura Oncology Inc |
Opened
1,000,000
|
$21,330,000,000 | 1.05% |
| Geron Corp. |
25.93%
6,000,000
|
$19,800,000,000 | 0.98% |
| Day One Biopharmaceuticals I |
No change
1,189,943
|
$19,657,858,000 | 0.97% |
| Third Harmonic Bio Inc |
250.62%
2,000,000
|
$18,880,000,000 | 0.93% |
| KalVista Pharmaceuticals Inc |
Opened
1,590,000
|
$18,857,400,000 | 0.93% |
| Exelixis Inc |
Closed
1,150,000
|
$18,446,000,000 | |
| Point Biopharma Global Inc |
Closed
2,500,000
|
$18,225,000,000 | |
| 89bio Inc |
Closed
1,400,000
|
$17,822,000,000 | |
| IVERIC bio Inc |
Closed
825,000
|
$17,663,250,000 | |
| Allogene Therapeutics Inc |
Opened
3,850,000
|
$17,209,500,000 | 0.85% |
| Rain Oncology Inc |
Closed
2,147,212
|
$17,177,696,000 | |
| Structure Therapeutics Inc |
Opened
400,000
|
$17,144,000,000 | 0.85% |
| Prothena Corp Plc |
130.00%
690,000
|
$17,091,300,000 | 0.84% |
| Sana Biotechnology Inc |
Opened
1,545,000
|
$15,450,000,000 | 0.76% |
| Relay Therapeutics, Inc. |
16.14%
1,819,132
|
$15,098,796,000 | 0.75% |
| Poseida Therapeutics, Inc. |
Opened
4,475,000
|
$14,275,250,000 | 0.71% |
| Nurix Therapeutics, Inc. |
Closed
1,224,892
|
$13,449,314,000 | |
| Engene Holdings Inc |
Opened
727,900
|
$12,337,905,000 | 0.61% |
| Prelude Therapeutics Inc |
Opened
2,568,287
|
$12,173,680,000 | 0.60% |
| Enliven Therapeutics Inc |
Opened
671,358
|
$11,809,187,000 | 0.58% |
| Ascendis Pharma A/S |
Closed
95,000
|
$11,602,350,000 | |
| Cullinan Oncology, LLC |
Closed
1,074,082
|
$11,331,565,000 | |
| Iovance Biotherapeutics Inc |
50.17%
750,000
|
$11,115,000,000 | 0.55% |
| Jasper Therapeutics Inc |
Opened
350,000
|
$10,276,000,000 | 0.51% |
| Boundless Bio Inc |
Opened
711,329
|
$10,136,438,000 | 0.50% |
| Spyre Therapeutics Inc |
Opened
250,000
|
$9,482,500,000 | 0.47% |
| Century Therapeutics Inc |
Opened
1,750,000
|
$7,315,000,000 | 0.36% |
| Gossamer Bio, Inc. |
Closed
3,336,928
|
$7,241,134,000 | |
| Zentalis Pharmaceuticals, Llc |
Opened
450,000
|
$7,092,000,000 | 0.35% |
| Panacea Acquisition Corp Ii |
Closed
500,000
|
$6,208,060,000 | |
| Cogent Biosciences, Inc. |
Closed
525,000
|
$6,069,000,000 | |
| Cabaletta Bio Inc |
Closed
540,000
|
$4,995,000,000 | |
| 2seventy Bio Inc |
Closed
459,836
|
$4,308,663,000 | |
| Amylyx Pharmaceuticals Inc |
28.02%
1,500,000
|
$4,260,000,000 | 0.21% |
| Absci Corporation |
Opened
700,000
|
$3,976,000,000 | 0.20% |
| Selecta Biosciences Inc |
Closed
3,284,072
|
$3,711,001,000 | |
| Kinnate Biopharma Inc. |
Closed
510,000
|
$3,111,000,000 | |
| Atara Biotherapeutics Inc |
Opened
4,150,000
|
$2,880,100,000 | 0.14% |
| Black Diamond Therapeutics I |
74.89%
506,000
|
$2,565,420,000 | 0.13% |
| Direxion Shs Etf Tr |
Opened
350,000
|
$2,551,500,000 | 0.13% |
| Ngm Biopharmaceuticals Inc |
Closed
500,000
|
$2,510,000,000 | |
| Health Sciences Acq Corp 2 |
Closed
250,000
|
$2,495,000,000 | |
| Eqrx Inc |
Closed
1,000,000
|
$2,460,000,000 | |
| BioAtla, Inc. |
No change
686,347
|
$2,361,034,000 | 0.12% |
| Theseus Pharmaceuticals Inc |
Closed
415,000
|
$2,066,700,000 | |
| Veru Inc |
Closed
347,300
|
$1,833,744,000 | |
| Atreca Inc |
Closed
2,202,333
|
$1,763,188,000 | |
| Mereo BioPharma Group plc |
Closed
2,250,000
|
$1,687,500,000 | |
| Orchestra Biomed Hldgs Inc |
Opened
238,193
|
$1,255,277,000 | 0.06% |
| Alaunos Therapeutics Inc |
Closed
1,500,000
|
$973,650,000 | |
| Protara Therapeutics Inc |
No change
209,227
|
$839,000,000 | 0.04% |
| MEI Pharma Inc |
Closed
2,913,091
|
$709,629,000 | |
| Milestone Pharmaceuticals In |
55.78%
309,007
|
$553,123,000 | 0.03% |
| Dbv Technologies S A |
65.52%
500,000
|
$374,550,000 | 0.02% |
| Disc Medicine Inc |
Closed
130,000
|
$175,500,000 | |
| Bellicum Pharmaceuticals Inc |
Closed
56,950
|
$41,004,000 | |
| No transactions found | |||
| Showing first 500 out of 92 holdings | |||
Hedge funds similar to Boxer Capital
- Greenlight Capital Inc
- St Germain D J Co Inc
- Unigestion S.A.
- Sowell Services
- Northeast Investment Management
- Fullerton Fund Management Co
- Swan Global Investments
- Ghp Investment Advisors
- Welch
- Clearstead Advisors
- Edge Capital
- First Western Trust Bank
- Dixon Mitchell Investment Counsel
- Polaris Capital Management